Two recent publications describe the mechanisms by which tasquinimod can act as a potential treatment alternative in multiple myeloma

S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. Lin C, Garcia-Gerique L, Bonner EE, Mastio J, Rosenwasser M, Cruz Z, Lawler M, Bernabei L, Muthumani K, Liu Q, Poncz M, Vogl T, Törngren M, Eriksson H, Vogl DT, Gabrilovich DI, Nefedova Y. Cancer Res Commun. 2023 Mar 13;3(3):420-430. Read the article here.

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H, Chantry A, De Beule N, Hose D, Törngren M, Eriksson H, Vanderkerken K, Maes K, Breckpot K, De Veirman K. J Immunother Cancer.  2023 Jan;11(1):e005319. Read the article here.